ASH 2020: Dr. Paolo Ghia Discusses the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia or CLL

You are here: